Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Julia M. K. Freind, Fernando R. Beserra, Bruno S. Menezes & Daniel C. Mograbi. (2023) Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review. Journal of Psychoactive Drugs 0:0, pages 1-17.
Read now
Read now
Anees Bahji, Carlos A. Zarate & Gustavo H. Vazquez. (2022) Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opinion on Drug Safety 21:6, pages 853-866.
Read now
Read now
Suresh D. Muthukumaraswamy, Anna Forsyth & Thomas Lumley. (2021) Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology 14:9, pages 1133-1152.
Read now
Read now
Alexandrine Corriger & Gisèle Pickering. (2019) Ketamine and depression: a narrative review. Drug Design, Development and Therapy 13, pages 3051-3067.
Read now
Read now
Matthew D. Cooper, Joshua D. Rosenblat, Danielle S. Cha, Yena Lee, Ron Kakar & Roger S. McIntyre. (2017) Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. The World Journal of Biological Psychiatry 18:6, pages 410-423.
Read now
Read now
Verònica Gálvez, Lucy McGuirk & Colleen K. Loo. (2017) The use of ketamine in ECT anaesthesia: A systematic review and critical commentary on efficacy, cognitive, safety and seizure outcomes. The World Journal of Biological Psychiatry 18:6, pages 424-444.
Read now
Read now
Paul Glue, Colleen Loo, Anthony Rodgers, Verònica Gálvez, Andrew A. Somogyi & Philip B. Mitchell. (2017) Comments on Cooper et al.’s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. The World Journal of Biological Psychiatry 18:6, pages 489-489.
Read now
Read now
Agnieszka Pałucha-Poniewiera & Andrzej Pilc. (2016) Glutamate-Based Drug Discovery for Novel Antidepressants. Expert Opinion on Drug Discovery 11:9, pages 873-883.
Read now
Read now
Eric J. Lenze, Nuri B. Farber, Evan Kharasch, Julie Schweiger, Michael Yingling, John Olney & John W. Newcomer. (2016) Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. The World Journal of Biological Psychiatry 17:3, pages 230-238.
Read now
Read now
Udo Bonnet. (2015) Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine’s Antidepressant Response and the Development of Ketamine Addiction. Journal of Psychoactive Drugs 47:4, pages 276-285.
Read now
Read now
Articles from other publishers (55)
Nicholas Hovda, Winslow Gerrish, William Frizzell & Ryan Shackelford. (2024) A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders. Journal of Affective Disorders 345, pages 262-271.
Crossref
Crossref
Steffen Reissmann, Matthias Hartmann, Andreas Kist, Matthias E. Liechti & Kurt Stocker. (2023) Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study. Frontiers in Psychiatry 14.
Crossref
Crossref
Stevan Nikolin, Anthony Rodgers, Andreas Schwaab, Anees Bahji, Carlos ZarateJr.Jr., Gustavo Vazquez & Colleen Loo. (2023) Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClinicalMedicine 62, pages 102127.
Crossref
Crossref
Colleen Loo, Nick Glozier, David Barton, Bernhard T. Baune, Natalie T. Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel Martin, Stevan Nikolin, Philip B. Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, Sean Hood, Andrew A. Somogyi, Kyle Lapidus, Elizabeth Stratton, Kirsten Gainsford, Deepak Garg, Nicollette L. R. Thornton, Célia Fourrier, Karyn Richardson, Demi Rozakis, Anish Scaria, Cathrine Mihalopoulos, Mary Lou Chatterton, William M. McDonald, Philip Boyce, Paul E. Holtzheimer, F. Andrew Kozel, Patricio Riva-Posse & Anthony Rodgers. (2023) Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. The British Journal of Psychiatry, pages 1-9.
Crossref
Crossref
Sina Dehestani, Amir Houshang Mohammadpour, Seyed Alireza Sadjadi, Thozhukat Sathyapalan & Amirhossein Sahebkar. (2023) Clinical use of ketamine in psychiatric disorders. Annales Médico-psychologiques, revue psychiatrique 181:6, pages 495-508.
Crossref
Crossref
Abhishek R. Giri, Nirmaljot Kaur, Siva Naga S. Yarrarapu, Kathleen A. Rottman Pietrzak, Christan Santos, Philip E. Lowman, Shehzad Niaz, Pablo Moreno Franco & Devang K. Sanghavi. (2022) “Novel Management of Depression Using Ketamine in the Intensive Care Unit”. Journal of Intensive Care Medicine 37:12, pages 1654-1661.
Crossref
Crossref
Heather M. Francis, Richard J. Stevenson, Lorraine S. Y. Tan, Lauren Ehrenfeld, Sooin Byeon, Tuki Attuquayefio, Dolly Gupta & Chai K. Lim. (2022) Kynurenic acid as a biochemical factor underlying the association between Western-style diet and depression: A cross-sectional study. Frontiers in Nutrition 9.
Crossref
Crossref
Ahmad Y. Abuhelwa, Andrew A. Somogyi, Colleen K. Loo, Paul Glue, Daniel T. Barratt & David J.R. Foster. (2022) Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment‐Refractory Depression. Clinical Pharmacology & Therapeutics 112:3, pages 720-729.
Crossref
Crossref
Shabah M. Shadli, Robert G. Delany, Paul Glue & Neil McNaughton. (2022) Right Frontal Theta: Is It a Response Biomarker for Ketamine’s Therapeutic Action in Anxiety Disorders?. Frontiers in Neuroscience 16.
Crossref
Crossref
Tácio de Mendonça Lima, Marília Berlofa Visacri & Patricia Melo Aguiar. (2021) Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. European Journal of Clinical Pharmacology 78:3, pages 311-338.
Crossref
Crossref
Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt & Celia J. A. Morgan. (2021) Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8:1.
Crossref
Crossref
Adam Bayes, Vanessa Dong, Donel Martin, Angelo Alonzo, Michael Kabourakis & Colleen Loo. (2021) Ketamine treatment for depression: A model of care. Australian & New Zealand Journal of Psychiatry 55:12, pages 1134-1143.
Crossref
Crossref
Anya Ragnhildstveit, Laura Kate Jackson, Sarah Cunningham, Linda Good, Quinn Tanner, Matthew Roughan & Patricia Henrie-Barrus. (2021) Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy. Frontiers in Psychiatry 12.
Crossref
Crossref
Wei Lee, Caitlin Sheehan, Richard Chye, Sungwon Chang, Colleen Loo, Brian Draper, Meera Agar & David C Currow. (2021) Study protocol for SKIPMDD: subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder (phase II pilot feasibility study). BMJ Open 11:6, pages e052312.
Crossref
Crossref
Samuel Kohtala. (2021) Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacological Reports 73:2, pages 323-345.
Crossref
Crossref
Maryam Tashakkori, Andrew Ford, Milan Dragovic, Laura Gabriel & Flavie Waters. (2020) The time course of psychotic symptom side effects of ketamine in the treatment of depressive disorders: a systematic review and meta-analysis. Australasian Psychiatry 29:1, pages 80-87.
Crossref
Crossref
Yan-Ling Zhou, Wei-Jian Liu, Cheng-Yu Wang, Wei Zheng, Xiao-Feng Lan, Sui-Yun Weng & Yu-Ping Ning. (2020) Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. Journal of Psychopharmacology 35:2, pages 159-167.
Crossref
Crossref
Aarti Gupta, Romika Dhar, Palak Patadia, Melissa Funaro, Gargi Bhattacharya, Syeda A. Farheen & Rajesh R. Tampi. (2020) A systematic review of ketamine for the treatment of depression among older adults. International Psychogeriatrics 33:2, pages 179-191.
Crossref
Crossref
Kyoung-Sae Na & Yong-Ku Kim. (2021) Increased use of ketamine for the treatment of depression: Benefits and concerns. Progress in Neuro-Psychopharmacology and Biological Psychiatry 104, pages 110060.
Crossref
Crossref
Raheel Imtiaz Memon, Sadiq Naveed, Amber Ehsan Faquih, Ania Fida, Noureen Abbas, Amna Mohyud Din Chaudhary & Zheala Qayyum. (2020) Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review. Psychiatric Quarterly 91:4, pages 1147-1192.
Crossref
Crossref
Isabella P. Fallon, Margaret K. Tanner, Benjamin N. Greenwood & Michael V. Baratta. (2019) Sex differences in resilience: Experiential factors and their mechanisms. European Journal of Neuroscience 52:1, pages 2530-2547.
Crossref
Crossref
Saurabh S. Kokane, Ross J. Armant, Carlos A. Bolaños-Guzmán & Linda I. Perrotti. (2020) Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behavioural Brain Research 384, pages 112548.
Crossref
Crossref
Meng Li, Marie Woelfer, Lejla Colic, Adam Safron, Catie Chang, Hans-Jochen Heinze, Oliver Speck, Helen S. Mayberg, Bharat B. Biswal, Giacomo Salvadore, Anna Fejtova & Martin Walter. (2018) Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects. European Archives of Psychiatry and Clinical Neuroscience 270:2, pages 207-216.
Crossref
Crossref
Ji-Woon Kim & Lisa M. Monteggia. (2020) Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways. Behavioural Brain Research 380, pages 112378.
Crossref
Crossref
Katrina Witt, Jennifer Potts, Anna Hubers, Michael F Grunebaum, James W Murrough, Colleen Loo, Andrea Cipriani & Keith Hawton. (2019) Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Australian & New Zealand Journal of Psychiatry 54:1, pages 29-45.
Crossref
Crossref
Samuel Kohtala, Wiebke Theilmann, Marko Rosenholm, Heidi K. Müller, Paula Kiuru, Gregers Wegener, Jari Yli-Kauhaluoma & Tomi Rantamäki. (2019) Ketamine-induced regulation of TrkB-GSK3β signaling is accompanied by slow EEG oscillations and sedation but is independent of hydroxynorketamine metabolites. Neuropharmacology 157, pages 107684.
Crossref
Crossref
C.H. Ng, T. Kato, C. Han, G. Wang, M. Trivedi, V. Ramesh, D. Shao, S. Gala, S. Narayanan, W. Tan, Y. Feng & S. Kasper. (2019) Definition of treatment-resistant depression – Asia Pacific perspectives. Journal of Affective Disorders 245, pages 626-636.
Crossref
Crossref
Jabril Eldufani, Alireza Nekoui & Gilbert Blaise. (2018) Nonanesthetic Effects of Ketamine: A Review Article. The American Journal of Medicine 131:12, pages 1418-1424.
Crossref
Crossref
Agnieszka Pałucha-Poniewiera. (2018) The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug. Pharmacological Reports 70:5, pages 837-846.
Crossref
Crossref
Sanya Virani, Navjot Brainch, Camila Albuquerque, Souparno Mitra, Maria Bodic & Lama Bazzi. (2018) Exploring the Role of Ketamine in Maintaining the Antidepressant Response. Psychiatric Annals 48:9, pages 437-446.
Crossref
Crossref
Li Ren, Jie Deng, Su Min, Lihua Peng & Qibin Chen. (2018) Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis. Journal of Psychiatric Research 104, pages 144-156.
Crossref
Crossref
Panos Zanos, Ruin Moaddel, Patrick J. Morris, Lace M. Riggs, Jaclyn N. Highland, Polymnia Georgiou, Edna F. R. Pereira, Edson X. Albuquerque, Craig J. Thomas, Carlos A. ZarateJr.Jr. & Todd D. Gould. (2018) Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews 70:3, pages 621-660.
Crossref
Crossref
Verònica Gálvez, Adrienne Li, Christina Huggins, Paul Glue, Donel Martin, Andrew A Somogyi, Angelo Alonzo, Anthony Rodgers, Philip B Mitchell & Colleen K Loo. (2018) Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology 32:4, pages 397-407.
Crossref
Crossref
Minling Zhang, Robert Rosenheck, Xiaoming Lin, Qirong Li, Yanling Zhou, Yunshan Xiao, Xiong Huang, Ni Fan & Hongbo He. (2018) A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. Journal of Affective Disorders 227, pages 372-378.
Crossref
Crossref
Laszlo Vutskits. (2018) General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms. Anesthesia & Analgesia 126:1, pages 208-216.
Crossref
Crossref
Colleen Loo. (2018) Can we confidently use ketamine as a clinical treatment for depression?. The Lancet Psychiatry 5:1, pages 11-12.
Crossref
Crossref
Brooke Short, Joanna Fong, Veronica Galvez, William Shelker & Colleen K Loo. (2018) Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry 5:1, pages 65-78.
Crossref
Crossref
Nuri B. Farber. 2019. Antidepressants. Antidepressants
287
305
.
Duncan George, Verònica Gálvez, Donel Martin, Divya Kumar, John Leyden, Dusan Hadzi-Pavlovic, Simon Harper, Henry Brodaty, Paul Glue, Rohan Taylor, Philip B. Mitchell & Colleen K. Loo. (2017) Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. The American Journal of Geriatric Psychiatry 25:11, pages 1199-1209.
Crossref
Crossref
Cameron Castle, Andrew Gray, Shona Neehoff & Paul Glue. (2017) Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology 31:10, pages 1306-1311.
Crossref
Crossref
Qibin ChenSu MinXuechao HaoLihua PengHuaqing MengQinghua LuoJianmei ChenXiao Li. (2017) Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy—A Randomized, Double-Blind, Controlled Clinical Study. The Journal of ECT 33:2, pages 89-95.
Crossref
Crossref
Marc S. Lener, Bashkim Kadriu & Carlos A. ZarateJrJr. (2017) Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs 77:4, pages 381-401.
Crossref
Crossref
Xiaomei Zhong, Hongbo He, Chunping Zhang, Zhijie Wang, Miaoling Jiang, Qirong Li, Minling Zhang & Xiong Huang. (2016) Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. Journal of Affective Disorders 201, pages 124-130.
Crossref
Crossref
William V. Bobo, Jennifer L. Vande Voort, Paul E. Croarkin, Jonathan G. Leung, Susannah J. Tye & Mark A. Frye. (2016) KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE. Depression and Anxiety 33:8, pages 698-710.
Crossref
Crossref
Roger C. M. Ho & Melvyn W. Zhang. (2018) Ketamine as a rapid antidepressant: the debate and implications. BJPsych Advances 22:4, pages 222-233.
Crossref
Crossref
C. K. Loo, V. Gálvez, E. O'Keefe, P. B. Mitchell, D. Hadzi-Pavlovic, J. Leyden, S. Harper, A. A. Somogyi, R. Lai, C. S. Weickert & P. Glue. (2016) Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica 134:1, pages 48-56.
Crossref
Crossref
T. Kishimoto, J. M. Chawla, K. Hagi, C. A. ZarateJr.Jr., J. M. Kane, M. Bauer & C. U. Correll. (2016)
Single-dose infusion ketamine and non-ketamine
N
-methyl-
d
-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
. Psychological Medicine 46:7, pages 1459-1472.
Crossref
Crossref
Colleen K. Loo & Ver?nica G?lvez. 2016. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
123
135
.
Colleen Loo. (2015) Is ketamine ready to be used clinically for the treatment of depression?. Medical Journal of Australia 203:11, pages 425-425.
Crossref
Crossref
Melvyn W Zhang & Roger C Ho. (2015) The paroxetine controversy: lessons for ketamine trials. The Lancet Psychiatry 2:12, pages 1057-1058.
Crossref
Crossref
Minkyung Park, Mark J. Niciu & Carlos A. ZarateJr.Jr.. (2015) Novel Glutamatergic Treatments for Severe Mood Disorders. Current Behavioral Neuroscience Reports 2:4, pages 198-208.
Crossref
Crossref
Carlos A. ZarateJr.Jr. & Mark J. Niciu. (2015) Ketamine for depression: evidence, challenges and promise. World Psychiatry 14:3, pages 348-350.
Crossref
Crossref
Alexander McGirr, Marcelo T. Berlim, David J. Bond, Nicholas H. Neufeld, Peter Y. Chan, Lakshmi N. Yatham & Raymond W. Lam. (2015) A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability. Journal of Psychiatric Research 62, pages 23-30.
Crossref
Crossref
Dmitri Souzdalnitski, Glenn R. Rech, Aleksandr Naydinskiy, Daria Suzdalnitskaya, Roman V. Isakov & Maged Guirguis. (2014) Ketamine in perioperative analgesia for knee surgeries: Review of evidence from randomized controlled trials. Techniques in Regional Anesthesia and Pain Management 18:4, pages 130-136.
Crossref
Crossref
Colleen Loo, Nicholas Glozier, David Barton, Bernhard Baune, Natalie Mills, Paul B. Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel M. Martin, Stevan Nikolin, Philip Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, Sean Hood, Andrew Somogyi, Kyle Lapidus, elizabeth stratton, Ellen Lyrtzis, Kirsten Gainsford, Shona Neehoff, Deepak Garg, Nicollette Thornton, Célia Fourrier, Karyn Richardson, Demi Rozakis, Anish Scaria, Cathrine Mihalopoulos, Mary Lou Chatterton, William McDonald, Philip Boyce, Paul Holtzheimer, Frank Andrew Kozel, Patricio Riva-Posse & Anthony Rodgers. (2022) Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial. SSRN Electronic Journal.
Crossref
Crossref